1 May 2017 - Company’s primary development focus is non-covalent reversible BTK inhibitor SNS-062.

Sunesis Pharmaceuticals announced today that the Company will withdraw its European marketing authorisation application for vosaroxin as a treatment for relapsed/refractory acute myeloid leukaemia in patients aged 60 years and older. 

The decision follows recent interactions with the EMA's CHMP, during which the Company learned that the committee was likely to formally adopt a negative opinion in its evaluation of the application.

Read Sunesis Pharmaceuticals press release